Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page
- Check6 days agoChange DetectedThe page revision has been updated from v3.5.2 to v3.5.3, reflecting a new template release. It does not change the displayed study details or layout for users.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0. This appears to be a minor site update with no changes to study records.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedRevision indicator updated to v3.5.0. The previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This indicates a software update rather than substantive content changes on the study page.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded Revision: v3.4.2; removed the long funding-status notice and Revision: v3.4.1. The update does not affect the study details or how the page is used.SummaryDifference0.3%

- Check91 days agoChange DetectedAdded a site-wide notice about government funding status and NIH CC operations. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.3%

Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.